Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 86 of 720 for:    Botulinum Toxins, Type A

Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02248844
Recruitment Status : Completed
First Posted : September 25, 2014
Last Update Posted : July 4, 2019
Sponsor:
Information provided by (Responsible Party):
Allergan

Brief Summary:
This is a postmarketing surveillance study in Korea to evaluate the safety and effectiveness of BOTOX® for lateral canthal lines (crow's feet lines) with or without simultaneous glabellar lines.

Condition or disease Intervention/treatment
Lateral Canthal Lines Crow's Feet Lines Biological: Botulinum Toxin Type A

Layout table for study information
Study Type : Observational
Actual Enrollment : 667 participants
Observational Model: Case-Only
Time Perspective: Prospective
Actual Study Start Date : September 26, 2014
Actual Primary Completion Date : August 14, 2017
Actual Study Completion Date : August 14, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Botox Foot Health

Group/Cohort Intervention/treatment
Botulinum Toxin Type A
Subjects who receive botulinum toxin Type A injected into crow's feet line areas per clinical practice.
Biological: Botulinum Toxin Type A
Botulinum toxin Type A injected into crow's feet line areas per clinical practice.
Other Names:
  • BOTOX®
  • onabotulinumtoxinA




Primary Outcome Measures :
  1. Number of Participants with Adverse Events [ Time Frame: Up to 3 months ]

Secondary Outcome Measures :
  1. Investigator's Assessment of Change in Appearance of Crow's Feet Lines on a 3-Point Scale [ Time Frame: Baseline, Up to 3 months ]
  2. Subject's Assessment of Change in Appearance of Crow's Feet Lines on a 7-Point Scale [ Time Frame: Baseline, Up to 3 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects with Lateral Canthal Lines (Crow's Feet Lines)
Criteria

Inclusion Criteria:

  • Subject and Investigator decision to treat crow's feet lines with Botox®

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02248844


Locations
Layout table for location information
Korea, Republic of
Dr. Robbin Clinic
Gangnam-gu, Seoul, Korea, Republic of, 135-839
Sponsors and Collaborators
Allergan
Investigators
Layout table for investigator information
Study Director: Medical Director Allergan

Additional Information:
Layout table for additonal information
Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT02248844     History of Changes
Other Study ID Numbers: 191622-147
First Posted: September 25, 2014    Key Record Dates
Last Update Posted: July 4, 2019
Last Verified: July 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Botulinum Toxins
Botulinum Toxins, Type A
abobotulinumtoxinA
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents